Upstate Dedicates Expanded Kinase Screening Facility in Dundee, Scotla

Upstate Dedicates Expanded Kinase Screening Facility in Dundee, Scotland

    Business Editors/Biotech Writers
    BIOWIRE2K

    ATLANTA--(BUSINESS WIRE)--March 8, 2005--

State-of-the-Art Facility Supports World's Largest Kinase Screening Panel and Company's Global Leadership Position
    Serologicals Corporation (NASDAQ: SERO) today announced that Upstate Group, its wholly-owned subsidiary, has completed the expansion of its kinase production and screening facility at its Dundee Center of Excellence in Dundee, Scotland. The facility generates and supports Upstate's kinase screening panel, the largest of its kind in the industry worldwide.
    "More than 25% of new drugs being developed today are based on kinase technology," said Ian Ratcliffe, President of Upstate. Upstate's share of the rapidly expanding global market of outsourced kinase screening services now exceeds 70%. Upstate's drug discovery business overall increased 42% in 2003 and 52% in 2004. The company's network of 300 cell signaling expert consultants is composed of key leaders in the field of drug discovery.
    Upstate's kinase screening panel provides quantitative characterization of compounds against a panel of 191 kinases in optimized assays. "That's significantly more than any other company can offer," said Ratcliffe, "and we expect to add over 100 new kinases to the panel in 2005."
    "Our expanded Dundee facility will allow us to meet the growing demand for Upstate's kinase screening services from customers worldwide, and will further support our industry-leading position in this critical area," said David A. Dodd, President and CEO, Serologicals Corporation. Mr. Dodd will be a featured speaker at the "Bio-Dundee Annual International Conference 2005" to be held March 17 and 18 at the Hilton Hotel Dundee.
    Kinases are proteins that play a critical role in the transmission of signals between and within cells. Aberrant or inappropriate kinase activity has been associated with as many as 400 diseases or conditions, including cancer, arthritis, diabetes, cardiovascular disease and neurological disorders.

    "Fischer Building" Opening Ceremony

    Upstate hosted a special dedication ceremony for the opening of its newly expanded facility on Tuesday, March 8, 2005. In attendance was Nobel Laureate Edmond H. Fischer, who was jointly awarded the 1992 Nobel Prize in Physiology or Medicine with Edwin Krebs for their breakthrough discoveries concerning reversible protein phosphorylation as a biological regulatory mechanism -- the scientific foundation which led to the understanding of the role of kinase proteins. In his honor, Upstate's new facility is named the "Fischer Building."
    Other attendees included the Honorable Jim Wallace, Retired Member of the Scottish Parliament, and currently Deputy First Minister and Minister for Enterprise & Lifelong Learning, who spoke at the event; and, David A. Dodd, President and CEO, Serologicals Corporation.
    Additional information about the opening ceremony can be obtained by contacting Steve Davies, Upstate Ltd., at +44 (0) 1382 561600, or visiting www.upstate.com.

    Upstate is a leading research discovery provider of the highest quality cell signaling products and services to the life science market. Its customers are biomedical researchers at drug discovery companies and academic institutions in the key disciplines of oncology, immunology, proteomics, cardiology and neurology. Known for its enabling, innovative solutions to help understand the biology of kinases, chromatin, g-proteins and cytokines, Upstate's advanced cell biology tools - drug screening services, enzymes, state specific antibodies, siRNA kits, multiplex assays are used by thousands of customers worldwide, every day to accelerate improving human health. Upstate, a Serologicals company, is headquartered in Charlottesville, VA, with locations in Lake Placid, NY, and Dundee, Scotland.
    For more information, please visit our website www.upstate.com.

    Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA, is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry.
    Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA.
    For more information, please visit our website: www.serologicals.com.
    Serologicals is a registered trademark of Serologicals Royalty Company.

--30--JAH/at*

CONTACT: Serologicals, Atlanta Bill Davis, 678/728-2018

KEYWORD: GEORGIA INDUSTRY KEYWORD: BANKING BIOTECHNOLOGY SOURCE: Serologicals Corporation

Copyright Business Wire 2005